Newsletter Oct 2014
19 Feb 2015
WWARN Published Date
Will you be attending the ASTMH 63rd Annual Meeting this year? Join WWARN’s sessions to hear about our latest projects and meet with the team to exchange ideas on how we might work together. - WWARN has worked closely with the Malaria in Pregnancy Consortium to investigate if resistance to former frontline antimalarial, sulfadoxine-pyrimethamine, can impact the effectiveness of intermittent preventive treatment in pregnancy, and whether this reduces the risk of low birth weight.
- An Imperial University-led Study Group is investigating how patient age, weight, and the drug dosage, can affect how long the commonly used antimalarial, artesunate-amodiaquine (ASAQ), protects patients against malaria infection when used as a preventative treatment.
- Last month, the Institut Pasteur and WWARN held a practical training workshop in Cambodia to share techniques with this valuable malaria resistance surveillance tool. Dr Naomi Lucchi, post-doctoral researcher at the Centers of Disease Control in Kisumu, Kenya shares her story on why the approaches will benefit CDC's research.
- The Plasmodium Diversity Network Africa is comprised of African researchers working on 17 projects in 15 countries working to explore the genetic and phenotypic diversity of Plasmodium falciparum.